These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 8346723)
1. Pharmacologic basis of the antiarrhythmic and hemodynamic effects of sotalol. Antonaccio MJ; Gomoll A Am J Cardiol; 1993 Aug; 72(4):27A-37A. PubMed ID: 8346723 [TBL] [Abstract][Full Text] [Related]
2. Hemodynamic effects of antiarrhythmic compounds: intrinsic effects and autonomic modulation. Hoffmeister HM; Beyer ME; Seipel L Am J Cardiol; 1997 Oct; 80(8A):24G-30G. PubMed ID: 9354409 [TBL] [Abstract][Full Text] [Related]
3. Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions. Holubarsch C; Schneider R; Pieske B; Ruf T; Hasenfuss G; Fraedrich G; Posival H; Just H Circulation; 1995 Nov; 92(10):2904-10. PubMed ID: 7586258 [TBL] [Abstract][Full Text] [Related]
4. Electrophysiologic and hemodynamic effects of H 234/09 (almokalant), quinidine, and (+)-sotalol in the anesthetized dog. Duker G; Almgren O; Carlsson L J Cardiovasc Pharmacol; 1992 Sep; 20(3):458-65. PubMed ID: 1279293 [TBL] [Abstract][Full Text] [Related]
5. Effects of nipradilol (K-351) on the electrophysiological properties of canine cardiac tissues: comparison with propranolol and sotalol. Nakaya H; Kimura S; Nakao Y; Kanno M Eur J Pharmacol; 1984 Sep; 104(3-4):335-44. PubMed ID: 6149947 [TBL] [Abstract][Full Text] [Related]
6. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs. Wallace AA; Stupienski RF; Brookes LM; Selnick HG; Claremon DA; Lynch JJ J Cardiovasc Pharmacol; 1991 Nov; 18(5):687-95. PubMed ID: 1723765 [TBL] [Abstract][Full Text] [Related]
7. Sotalol: An important new antiarrhythmic. Anderson JL; Prystowsky EN Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618 [TBL] [Abstract][Full Text] [Related]
8. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome. Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304 [TBL] [Abstract][Full Text] [Related]
9. Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents. Singh BN Am J Cardiol; 1993 Aug; 72(4):8A-18A. PubMed ID: 8346731 [TBL] [Abstract][Full Text] [Related]
10. Plasma concentrations and haemodynamic effects of d-sotalol after beta-blockade in dogs. Mortensen E; Tande PM; Kløw NE; Refsum H Pharmacol Toxicol; 1990 Nov; 67(5):420-5. PubMed ID: 1982898 [TBL] [Abstract][Full Text] [Related]
11. Inotropic and haemodynamic effects of d- and d,l-sotalol: comparison with other antiarrhythmics. Seipel L; Hoffmeister HM Eur Heart J; 1993 Nov; 14 Suppl H():36-40. PubMed ID: 7904937 [TBL] [Abstract][Full Text] [Related]
12. Effects of WAY-123,398, a new class III antiarrhythmic agent, on cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs: a comparison with UK-68798, E-4031, and dl-sotalol. Spinelli W; Parsons RW; Colatsky TJ J Cardiovasc Pharmacol; 1992 Dec; 20(6):913-22. PubMed ID: 1282594 [TBL] [Abstract][Full Text] [Related]
13. Electrophysiologic properties of sotalol and d-sotalol. A current view. Touboul P Eur Heart J; 1993 Nov; 14 Suppl H():24-9. PubMed ID: 7904935 [TBL] [Abstract][Full Text] [Related]
14. Class III antiarrhythmic action linked with positive inotropy: effects of the d- and l-isomer of sotalol on isolated rat atria at threshold and suprathreshold stimulation. Tande PM; Refsum H Pharmacol Toxicol; 1988 May; 62(5):272-7. PubMed ID: 3413029 [TBL] [Abstract][Full Text] [Related]
15. Effects of intravenous azimilide on cardiac performance, fibrillation threshold, and hemodynamics in anesthetized dogs. Brooks RR; Finch SL Arzneimittelforschung; 2000 Jul; 50(7):597-605. PubMed ID: 10965415 [TBL] [Abstract][Full Text] [Related]
16. The class III antiarrhythmic effect of sotalol exerts a reverse use-dependent positive inotropic effect in the intact canine heart. Peralta AO; John RM; Gaasch WH; Taggart PI; Martin DT; Venditti FJ J Am Coll Cardiol; 2000 Oct; 36(4):1404-10. PubMed ID: 11028502 [TBL] [Abstract][Full Text] [Related]
17. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol. Merot J; Charpentier F; Poirier JM; Coutris G; Weissenburger J Cardiovasc Res; 1999 Nov; 44(2):303-14. PubMed ID: 10690307 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol. Funck-Brentano C Eur Heart J; 1993 Nov; 14 Suppl H():30-5. PubMed ID: 7904936 [TBL] [Abstract][Full Text] [Related]
19. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies. Ducroq J; Printemps R; Guilbot S; Gardette J; Salvetat C; Le Grand M J Pharmacol Toxicol Methods; 2007; 56(2):159-70. PubMed ID: 17604185 [TBL] [Abstract][Full Text] [Related]
20. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Nakaya H; Tohse N; Takeda Y; Kanno M Br J Pharmacol; 1993 May; 109(1):157-63. PubMed ID: 7684298 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]